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Objectives The purpose of this study was to determine the respiratory, hemodynamic, and clinical effects of switching be-
tween 1-selective and nonselective beta-blockers in patients with chronic heart failure (CHF) and chronic ob-
structive pulmonary disease (COPD).
Background Carvedilol, metoprolol succinate, and bisoprolol are established beta-blockers for treating CHF. Whether differ-
ences in beta-receptor specificities affect lung or vascular function in CHF patients, particularly those with coexis-
tent COPD, remains incompletely characterized.
Methods A randomized, open label, triple-crossover trial involving 51 subjects receiving optimal therapy for CHF was con-
ducted in 2 Australian teaching hospitals. Subjects received each beta-blocker, dose-matched, for 6 weeks be-
fore resuming their original beta-blocker. Echocardiography, N-terminal pro-hormone brain natriuretic peptide,
central augmented pressure from pulse waveform analysis, respiratory function testing, 6-min walk distance,
and New York Heart Association (NYHA) functional class were assessed at each visit.
Results Of 51 subjects with a mean age of 66  12 years, NYHA functional class I (n  6), II (n  29), or III
(n  16), and left ventricular ejection fraction mean of 37  10%, 35 had coexistent COPD. N-terminal pro-
hormone brain natriuretic peptide was significantly lower with carvedilol than with metoprolol or bisoprolol
(mean: carvedilol 1,001 [95% confidence interval (CI): 633 to 1,367] ng/l; metoprolol 1,371 [95% CI: 778 to
1,964] ng/l; bisoprolol 1,349 [95% CI: 782 to 1,916] ng/l; p  0.01), and returned to baseline level on resump-
tion of the initial beta-blocker. Central augmented pressure, a measure of pulsatile afterload, was lowest with
carvedilol (carvedilol 9.9 [95% CI: 7.7 to 12.2] mm Hg; metoprolol 11.5 [95% CI: 9.3 to 13.8] mm Hg; bisoprolol
12.2 [95% CI: 9.6 to 14.7] mm Hg; p  0.05). In subjects with COPD, forced expiratory volume in 1 s was lowest
with carvedilol and highest with bisoprolol (carvedilol 1.85 [95% CI: 1.67 to 2.03] l/s; metoprolol 1.94 [95% CI:
1.73 to 2.14] l/s; bisoprolol 2.0 [95% CI: 1.79 to 2.22] l/s; p  0.001). The NYHA functional class, 6-min walk
distance, and left ventricular ejection fraction did not change. The beta-blocker switches were well tolerated.
Conclusions Switching between 1-selective beta-blockers and the nonselective beta-blocker carvedilol is well tolerated but
results in demonstrable changes in airway function, most marked in patients with COPD. Switching from 1-
selective beta-blockers to carvedilol causes short-term reduction of central augmented pressure and N-terminal
pro-hormone brain natriuretic peptide. (Comparison of Nonselective and Beta1-Selective Beta-Blockers on Respi-
ratory and Arterial Function and Cardiac Chamber Dynamics in Patients With Chronic Stable Congestive Cardiac
Failure; Australian New Zealand Clinical Trials Registry, ACTRN12605000504617) (J Am Coll Cardiol 2010;
55:1780–7) © 2010 by the American College of Cardiology Foundation
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April 27, 2010:1780–7 Beta-Blockade in Heart Failure and COPDandomized controlled trials have demonstrated that carve-
ilol (1), metoprolol succinate (2), and bisoprolol fumarate
3) all improve survival in patients with chronic heart failure
CHF). These beta-blockers differ, however, in their phar-
acological characteristics. The nonselective beta-blocker
arvedilol has similar affinity for both 1- and 2-receptors
s well as -blocking capacity, whereas metoprolol and
isoprolol have greater selective affinity for 1- than 2-
eceptors, which predominate in the lungs. These beta-
lockers, particularly the nonselective beta-blockers, are still
nderprescribed to patients with coexistent chronic obstructive
ulmonary disease (COPD) and CHF, largely because of
oncern about precipitating respiratory deterioration. This is an
mportant consideration as the prevalence of COPD in pa-
ients with CHF ranges between 20% and 32% (4). Evidence
onfirms that the benefits of 1-selective beta-blockers (B1B)
n these patients outweigh the risks (5), with data also for
arvedilol (6). Limited information, however, exists regarding
he safety of switching between these beta-blockers. This study
ssessed the respiratory, hemodynamic, and clinical effects of
witching between B1B and nonselective beta-blockers in
atients with CHF and COPD.
ethods
esign, settings, and participants. The open-label, ran-
omized, triple-crossover study was conducted in the heart
ailure clinics of St. Vincent’s Hospital (Sydney, New South
ales, Australia) and The Alfred Hospital (Melbourne,
ictoria, Australia). In all, 51 CHF patients with stable
ew York Heart Association (NYHA) functional classes I
hrough III symptoms, already receiving a beta-blocker in
ddition to standard CHF therapy including angiotensin-
onverting enzyme inhibitors and/or angiotensin-receptor
ntagonists, spironolactone, and digoxin were enrolled. A
ubgroup of 35 (69%) patients with coexistent COPD
meeting GOLD criteria [7]) was enrolled. Patients with a
ecent or unstable heart failure diagnosis, recent myocardial
nfarction, biventricular pacemaker implantation, revascu-
arization, or history of significant intolerance to any of the
CHF beta-blockers were excluded. Demographics be-
ween the CHF patients with and without COPD were not
ignificantly different (Table 1).
The study was approved by local ethics committees and
egistered with the Australian New Zealand Clinical Trials
egistry (ACTRN12605000504617). All patients gave
ritten informed consent.
andomization and interventions. Following baseline in-
estigations, patients were randomly switched (8) to a
ose-matched beta-blocker (Table 2). The second beta-
straZeneca. Dr. Krum has received grant funding from Roche, Alpha-Pharma, and
erck CSL. Assoc. Prof. Hayward has received grant funding from Pfizer, and
onoraria/travel grants from AstraZeneca, Roche, and Alpha-Pharma, CSL Biotherapies,
nd Merck.b
Manuscript received November 9, 2009; revised manuscript received January 8,
010, accepted January 11, 2010.locker, which had to be differ-
nt from the subject’s baseline
reatment, was administered for
weeks before reassessment of
utcome measures and crossover
o the third beta-blocker for an-
ther 6 weeks and reassessment.
ubjects then resumed their orig-
nal beta-blocker and were reas-
essed 4 weeks later for compar-
son with baseline (Fig 1).
utcomes and follow-up. The
rimary outcome measure was post-
ronchodilator forced expiratory
olume in 1 s (FEV1). Secondary
utcome measures were changes
n bronchodilator response, large
rterial and cardiac chamber
unction as measured by pulse
aveform analysis and echocar-
iography, 6-min walk distance (6MWD), and biochemical
arkers of heart failure severity. Outcomes were measured
t baseline and at 6, 12, and 16 weeks.
Spirometry and 6MWD were performed in accordance
ith American Thoracic Society (ATS) guidelines. The radial
rterial pressure waveform was recorded noninvasively by
pplanation tonometry at the wrist (SphygmoCor Px Version
.1, ATCOR Medical P/L, West Ryde, Australia). Standard
ransthoracic echocardiograms were performed as per Ameri-
an Society of Echocardiography guidelines and reported by a
linded cardiologist. Blood samples were collected for NT-
roBNP, creatinine, sodium, and bilirubin. Supine, brachial
lood pressure was measured using an automatic sphygmoma-
ometer (Welch Allyn Spot Vital Signs, Model 5200–103Z,
elch Allyn, Skaneateles Falls, New York). Three consecutive
eadings were obtained, and the average of the last 2 recorded.
his was repeated after 2 min standing. Weight and resting
upine heart rate were also recorded.
tatistical analysis. Sample size was based on 80% power
o detect an absolute change of 150 ml in post-bronchodilator
EV1, assuming 2-sided tests and an alpha value of 0.05 (9).
esults are reported as mean with 95% confidence intervals
CIs). Outcomes were analyzed by repeated measures analysis
f variance with Bonferroni correction. Friedman’s test with
ost-hoc Dunn’s multiple comparison test was performed for
onparametric N-terminal pro-hormone brain natriuretic pep-
ide (NT-proBNP) subgroup data analysis. Statistical analyses
ere performed on SPSS for Windows version 17.0 (SPSS
nc., Chicago, Illinois) and Prism version 5.0 (GraphPad
oftware, Inc., San Diego, California) for NT-proBNP
raphic and analysis.
esults
he FEV1 was significantly higher among patients receiving
Abbreviations
and Acronyms
B1B  1-selective
beta-blockers
CHF  chronic heart failure
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
FEV1  forced expiratory
volume in 1 s
FVC  forced vital capacity
NT-proBNP  N-terminal
pro-hormone brain
natriuretic peptide
NYHA  New York Heart
Association
6MWD  6-min walk
distanceisoprolol compared with carvedilol, both in subjects with
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Beta-Blockade in Heart Failure and COPD April 27, 2010:1780–7oexistent COPD (150 ml, 95% CI: 40 to 260 ml; p 0.01)
nd without (120 ml, 95% CI: 20 to 220 ml; p  0.02)
Table 3). A similar, but slightly less marked difference was
oted between carvedilol and metoprolol (80 ml, 95% CI:
0 to 150 ml; p  0.04). No difference in FEV1 was noted
etween B1Bs. The FVC remained unchanged. There was
lso no significant change in bronchodilator responsiveness
etween treatments.
Brachial blood pressure was unchanged between treat-
Baseline CharacteristicsTable 1 Baseline Characteristics
CO
(
Age, yrs, mean (SD) [range] 68
Male, n (%) 26
Etiology, n (%)
Idiopathic dilated 12
Familial 2
Ischemic 21
NYHA functional class, n (%)
I 3
II 20
III 12
Baseline beta-blocker, n (%)
Carvedilol 26
Metoprolol succinate 2
Bisoprolol 7
Baseline beta-blocker dose, mg, mean (SD)
Carvedilol 30.3
Metoprolol succinate 121.3
Bisoprolol 6.3
Other medications, n (%)
ACE inhibitors or A2RAs 32
Aldosterone antagonist 13
Nitrates 12
Digoxin 12
Diuretics 23
SBP, mm Hg, mean (SD) [range] 113
DBP, mm Hg, mean (SD) [range] 68
LVEF, %, mean (SD) 35
Atrial fibrillation, n (%) 5
NT-proBNP, ng/l, mean (SD) 1,279
Baseline inhaler usage, n (%)
Tiotropium bromide 8
Ipratropium bromide 1
Terbutaline sulfate 3
Fluticasone propionate; salmeterol xinafoate 9
Fluticasone propionate 1
Hydrocortisone acetate 2
Budesonide 1
COPD severity (GOLD [7]), n (%)
Mild 5
Moderate 23
Severe 7
ACE  angiotensin-converting enzyme; A2RA  angiotensin-II recep
pulmonary disease; DBP diastolic blood pressure; LVEF left ventric
peptide; NYHA  New York Heart Association; SBP  systolic blood pents. However, central augmented pressure was lowest on varvedilol, with a reduction of 2.3 mm Hg (p  0.03)
ompared with bisoprolol and 1.6 mm Hg (p  0.05)
ompared with metoprolol (Table 4). A reduction in heart
ate of 4.0 beats/min (p  0.03) was also noted between
arvedilol and bisoprolol. Notably, NT-proBNP levels were
owest in subjects when receiving carvedilol (Table 5).
In the subgroup of patients who commenced the study on
arvedilol, NT-proBNP and respiratory function tests were
erformed 4 weeks after resuming carvedilol, at the final
CHF
)
CHF Only
(n  16)
Total
(n  51)
7–88] 63 (13) [27–82] 66 (12) [27–88]
14 (88) 40 (78)
7 (44) 19 (37)
2 (12) 4 (8)
7 (44) 28 (55)
3 (19) 6 (12)
9 (56) 29 (57)
4 (25) 16 (31)
9 (56) 35 (69)
2 (13) 4 (8)
5 (31) 12 (23)
42.4 (15.9) 33.4 (23.5)
) 59.4 (50.4) 90.3 (75.8)
7.5 (3.5) 6.8 (3.6)
12 (75) 44 (87)
6 (38) 19 (37.3)
3 (19) 15 (29.4)
5 (31) 17 (33.3)
10 (63) 33 (64.7)
8–139] 117 (14) [93–145] 115 (16) [78–145]
6–84] 72 (9) [55–85] 69 (10) [46–85]
40 (10) 37 (10)
2 (13) 7 (14)
) 758 (921) 1,112 (1,235)
1 (6) 9 (18)
0 (0) 1 (2)
0 (0) 3 (6)
3 (19) 12 (24)
0 (0) 1 (2)
1 (6) 3 (6)
0 (0) 1 (2)
0 5 (10)
0 23 (45)
0 7 (14)
tagonist; CHF  chronic heart failure; COPD  chronic obstructive
ction fraction; NT-proBNP N-terminal pro-hormone brain natriuretic
.PD 
n  35
(11) [2
(74)
(34)
(6)
(60)
(9)
(57)
(34)
(74)
(6)
(20)
(25.1)
(104.3
(3.8)
(91)
(37)
(34)
(34)
(66)
(16) [7
(10) [4
(10)
(14)
(1,338
(23)
(3)
(9)
(26)
(3)
(6)
(3)
(14)
(66)
(20)
tor an
ular ejeisit. Figure 2 demonstrates NT-proBNP returning to
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April 27, 2010:1780–7 Beta-Blockade in Heart Failure and COPDaseline levels in these patients after rising significantly
uring the study (p  1.0). Similarly, Figure 3 demon-
trates FEV1 returning to baseline levels on resumption
f carvedilol.
afety. A total of 7 patients (14%) withdrew from the
tudy. No withdrawals occurred when patients were
witched from a B1B to carvedilol. Two patients (4%)
ithdrew after switching between B1Bs, 1 for social reasons
nd the other for dyspnea. Five patients (10%) withdrew
fter switching from carvedilol to a B1B (3 carvedilol to
etoprolol [with dyspnea]; 2 carvedilol to bisoprolol [1
ancreatic cancer, 1 dyspnea and angina]. Most patients
escribed mild lethargy and dyspnea immediately after
witching beta-blockers that generally subsided within a
eek. Full report of adverse events is outlined in Table 6.
iscussion
his is the first study to demonstrate significant differences
etween carvedilol, metoprolol succinate, and bisoprolol in
atients with stable CHF and coexistent COPD tolerating
eta-blocker therapy. Specifically, switching between B1Bs
nd carvedilol results in demonstrable changes in airway
ose Equivalence of Beta-Blockers Used in StudyTable 2 Dose Equivalence of Beta-Blockers Used in Study
Carvedilol Metoprolol Succinate Bisoprolol
3.125 mg bid 23.75 mg od 1.25 mg od
6.25 mg bid 47.5 mg od 2.5 mg od
12.5 mg bid 95 mg od 5 mg od
25 mg bid 190 mg od 10 mg od
50 mg bid 380 mg od 20 mg od
id  twice daily; od  daily.
Enroll
Carvedilol
(n=35)
Baseline Assessment
Random assignment
Bis
Baselin
Rando
Bisoprolol
(n=25)
Withdrawn (n=2) 
1 Cancer 
1 Dyspnea, angina 
Metoprolol
(n=10)
Withdrawn (n=2)
2 Dyspnea
Carvedilol
(n=6)
Metoprolol
(n=23)
Lost to follow up (n=2)
1 Lung Cancer
1 Social
Bisoprolol
(n=8)
Withdrawn (n=1)
1 Dyspnea
Metoprolol
(n=6) 
Withdrawn (n=1)
1 Dyspnea
Carvedilol
(n=28) BisFigure 1 Flowchart of Study Participantsunction, and switching from B1Bs to carvedilol causes
hort-term reduction of central augmented pressure and
T-proBNP.
espiratory function. Studies have shown that FEV1 is
ot significantly worsened by 1-selective beta-blockade in
atients with COPD (5), and although few data exist
egarding the effects of carvedilol on FEV1 in COPD, a
ignificant difference in FEV1 between B1Bs and carvedilol
as observed in our study. Further, the magnitude of
ifference was similar to observed FEV1 improvements in
tudies of tiotropium in COPD (10). Despite this, no excess
ntolerance was observed changing from bisoprolol to carve-
ilol, likely related to the lack of post-bronchodilator
eversibility of large airway function—as would be expected
n a stable COPD cohort.
T-proBNP. NT-proBNP is a powerful prognostic marker
n CHF (11). In our study, median NT-proBNP levels were
owest on carvedilol compared with bisoprolol and metoprolol.
nalysis of the COMET (Carvedilol Or Metoprolol Euro-
ean Trial) data concluded that the achieved median NT-
roBNP concentration after beta-blocker treatment is a pre-
ictor of mortality (11). Bettencourt et al. (12) showed that
uring hospitalization for acute decompensated heart failure,
ack of a significant (30%) decrease in NT-proBNP was
ssociated with adverse outcome when compared with patients
n whom NT-proBNP decreased significantly (30%). In our
tudy, 50% of patients had a 30% increase and only 9% had
30% decrease of NT-proBNP after switching from carve-
ilol to a B1B. By contrast, switching from metoprolol to
isoprolol yielded mixed findings, with only 21% experiencing
30% increase and 14% a 30% decrease in NT-proBNP.
his is the first description of changes in NT-proBNP levels in
ients
ol
ment
ment
Metoprolol
(n=4)
Baseline Assessment
Random assignment
Metoprolol
(n=6)
Withdrawn (n=1) 
1 Social
Bisoprolol
(n=3)
Carvedilol
(n=1)
Carvedilol
(n=5)
Carvedilol
(n=3)
Bisoprolol
(n=1)
ol Metoprolol
(n=4)ed Pat
(n=51)
oprol
(n=12)
e Assess
m assign
oprol
(n=10)
Respiratory Function OutcomesTable 3 Respiratory Function Outcomes
Between-Treatment Difference*
Outcome Carvedilol Metoprolol Bisoprolol Carvedilol-Metoprolol p Value Carvedilol-Bisoprolol p Value Metoprolol-Bisoprolol p Value
FEV1 post-bronchodilator, l/s
COPDCHF 1.85 (1.67 to 2.03) 1.93 (1.73 to 2.14) 2.00 (1.79 to 2.22) 0.08 (0.18 to 0.01) 0.09 0.15 (0.26 to0.04) 0.01 0.07 (0.17 to 0.04) 0.32
CHF 2.61 (2.23 to 2.98) 2.67 (2.32 to 3.03) 2.72 (2.29 to 3.15) 0.07 (0.21 to 0.08) 0.71 0.12 (0.22 to0.02) 0.02 0.05 (0.22 to 0.12) 1.0
All subjects 2.07 (1.88 to 2.26) 2.15 (1.95 to 2.35) 2.21 (2.00 to 2.43 0.08 (0.15 to0.01) 0.04 0.14 (0.22 to0.06) 0.001 0.06 (0.14 to 0.02) 0.20
Forced vital capacity, l
COPDCHF 3.20 (2.96 to 3.43) 3.23 (2.95 to 3.50) 3.32 (3.04 to 3.61) 0.03 (0.19 to 0.13) 1 0.13 (0.29 to 0.03) 0.16 0.10 (0.22 to 0.03) 0.18
CHF 3.44 (2.95 to 3.93) 3.46 (2.96 to 3.97) 3.51 (2.97 to 4.06) 0.02 (0.22 to 0.17) 1.0 0.08 (0.20 to 0.05) 0.34 0.05 (0.26 to 0.16) 1.0
All subjects 3.27 (3.06 to 3.48) 3.30 (3.06 to 3.53) 3.38 (3.13 to 3.62) 0.03 (0.15 to 0.09) 1.0 0.11 (0.23 to 0.003) 0.06 0.08 (0.19 to 0.02) 0.14
Bronchodilator response,
FEV1 (% increase)
COPDCHF 5.9 (3.0 to 8.8) 9.0 (5.5 to 12.6) 7.1 (3.5 to 10.6) 3.1 (7.7 to 1.4) 0.27 1.1 (6.3 to 4.0) 1.0 2.0 (3.8 to 7.7) 1.0
CHF 2.5 (0.3 to 4.7) 4.1 (2.0 to 6.1) 6.6 (3.2 to 10.1) 1.6 (5.4 to 2.3) 0.82 4.1 (7.5 to0.8) 0.02 2.6 (7.2 to 2.1) 0.44
All subjects 4.9 (2.8 to 7.1) 7.6 (5.0 to 10.2) 6.9 (4.3 to 9.6) 2.7 (6.0 to 0.6) 0.15 2.0 (5.7 to 1.7) 0.53 0.7 (3.6 to 4.9) 1.0
Values are median (interquartile range). *Between-treatment difference, mean (95% confidence interval).
FEV1  forced expiratory volume in 1 s; other abbreviations as in Table 1.
Secondary OutcomesTable 4 Secondary Outcomes
Between-Treatment Difference*
Outcome Carvedilol Metoprolol Bisoprolol Carvedilol-Metoprolol p Value Carvedilol-Bisoprolol p Value Metoprolol-Bisoprolol p Value
Clinical
Heart rate, beats/min 66.4 (62.7 to 70.1) 64.5 (60.3 to 68.7) 62.5 (58.7 to 66.2) 1.9 (2.3 to 6.2) 0.79 4.0 (0.2 to 7.7) 0.03 2.0 (0.7 to 4.8) 0.2
SBP, mm Hg 116 (111 to 121) 117 (112 to 123) 117 (112 to 122) 1.6 (7.4 to 4.2) 1.0 1.1 (6.3 to 4.1) 1.0 0.5 (5.5 to 4.5) 1.0
DBP, mm Hg 69 (66 to 72) 70 (68 to 73) 69 (66 to 72) 1.5 (4.6 to 1.8) 0.85 0.2 (3.2 to 2.8) 1.0 1.2 (1.1 to 3.6) 0.60
Pulse wave analysis
Central augmented pressure, mm Hg 9.9 (7.7 to 12.2) 11.5 (9.3 to 13.8) 12.2 (9.6 to 14.7) 1.6 (3.2 to 0.0) 0.05 2.3 (4.3 to0.2) 0.03 0.7 (3.0 to 1.7) 1.0
Biochemistry
Creatinine, mol/l 113 (99 to 127) 112 (95 to 128) 114 (98 to 130) 1.4 (7.4 to 10.2) 1.0 1.2 (8.1 to 5.8) 1.0 2.6 (10.2 to 5.1) 1.0
Sodium, mmol/l 140 (139 to 141) 139 (137 to 140) 139 (138 to 141) 1.2 (0.2 to 2.5) 0.11 0.3 (1.0 to 1.6) 1.0 0.9 (2.0 to 0.3) 0.23
Bilirubin, mol/l 13 (11 to 15) 14 (12 to 15) 13 (11 to 14) 0.7 (2.1 to 0.7) 0.67 0.1 (1.1 to 1.4) 1.0 0.8 (0.6 to 2.4) 0.52
Function
6MWD 393 (361 to 426) 387 (358 to 416) 403 (373 to 434) 6 (12 to 25) 1.0 10 (27 to 7) 0.44 16 (32 to1) 0.03
Echocardiography
LVEDD 62 (59 to 64) 62 (59 to 65) 62 (59 to 65) 0.1 (2.1 to 1.9) 1.0 0.7 (3.0 to 1.6) 1.0 0.6 (2.2 to 1.0) 1.0
LVESD 50 (47 to 54) 50 (46 to 53) 51 (48 to 54) 0.3 (2.1 to 2.7) 1.0 1.1 (3.3 to 1.0) 0.60 1.4 (3.4 to 0.6) 0.24
Ejection fraction, % 36 (33 to 40) 36 (32 to 39) 37 (34 to 40) 0.9 (1.7 to 3.6) 1.0 0.7 (3.2 to 1.8) 1.0 1.7 (4.3 to 0.9) 0.35
Values are median (interquartile range). *Between-treatment difference, mean (95% confidence interval); p value, multiple comparison with Bonferroni adjustment.
LVEDD  left ventricular end diastolic dimension; LVESD  left ventricular end systolic dimension; 6MWD  6-min walk distance; other abbreviations as in Table 1.
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April 27, 2010:1780–7 Beta-Blockade in Heart Failure and COPDmatched cohort of patients with CHF receiving carvedilol,
etoprolol succinate, and bisoprolol.
linical effects. We observed no change in brachial artery
ressure; however, central augmented pressure, measured by
oninvasive tonometric pressure wave recordings, was low-
st on carvedilol, consistent with decreased wave reflection
ue to the -blocking effect of the drug. The lower central
ulsatile afterload with carvedilol demonstrated in this study
ay further provide a hemodynamic explanation for the
ower NT-proBNP with this drug.
The 6MWD assesses functional capacity and is of prog-
ostic value for patients with CHF and COPD (13). There
as no clinically significant difference between beta-
Figure 2 Median NT-proBNP Levels
Median N-terminal pro-hormone brain natriuretic peptide (NT-proBNP) levels in
the subgroup of subjects who commenced the study on carvedilol (C). *p 
0.01; §p  1.0 compared with carvedilol at baseline. Error bars represent
interquartile range.
Figure 3 FEV1 of Subjects Who Commenced
the Study on Carvedilol
Forced expiratory volume in 1 second (FEV1) of subgroup of subjects who com-
menced the study on carvedilol (C). *p  0.02 compared with baseline; §p 
1.0 compared with carvedilol at baseline and p  0.02 compared with bisopro-
lol. Error bars represent 95% confidence intervals.N
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Beta-Blockade in Heart Failure and COPD April 27, 2010:1780–7lockers in our study. This further validates findings by
etra et al. (14), who showed similar improvements in
MWD between metoprolol tartrate and carvedilol in a
eterogeneous group of patients with CHF. No changes in
eft ventricular dimensions or ejection fraction were de-
ected, also consistent with current research in CHF (15).
afety. The tolerability of beta-blockers in COPD is of
mportance as underprescription has been attributed to
hysicians’ perception of patient intolerance (4). We have
reviously shown that patients with CHF and coexistent
OPD without reversible airflow obstruction tolerate carve-
ilol well (6). In 1 study, 76 of 89 such patients (85%)
olerated carvedilol (16). A randomized trial of 87 CHF
atients demonstrated no difference in the tolerability of
arvedilol and bisoprolol, although the incidence of COPD
n their cohort was not specified (17). Metoprolol was also
ell tolerated in a small study of patients with ischemic
eart disease and COPD (18).
There were 5 (10%) drug-related adverse events necessi-
ating withdrawal from our study, 4 (8%) occurred after
arvedilol was switched to a B1B, and 1 (2%) occurred when
witching from metoprolol to bisoprolol. No withdrawals
ccurred after switching from a B1B to carvedilol. Our
tudy provides additional evidence for the tolerability of
arvedilol by patients with CHF and coexistent COPD and
lso suggests that switching from B1Bs to carvedilol is safe.
ur data are in agreement with results from the post-study
hase of the COMET study, which revealed CHF-related
vent rates of 4.7% for patients switching from carvedilol to
etoprolol and 1.5% for patients switching from metoprolol
o carvedilol (19).
Switches between beta-blockers were undertaken without
emporary dose reduction to minimize potential risk of wors-
ning CHF and arrhythmias after withdrawal of beta-blockade
20). Although switches were generally safe, most patients
escribed mild worsening of their heart failure symptoms
dverse Events After Switching Beta-BlockersTable 6 Adverse Events After Switching Beta-Blockers
Adverse Event C to B
Edema or weight gain 2 (4)
Pre-syncope —
Intermittent claudication —
Angina 1 (2)
Dyspnea 1 (2)
Wheeze —
Bradycardia —
Deterioration of renal function 1 (2)
Hospital admission for CHF treatment —
Minor AE requiring temporary beta-blocker dose reduction —
Minor AE requiring diuretic increase 3
Minor AE requiring early switch —
AE requiring withdrawal from study* 1 (2)
alues are n (%). *All drug-related adverse events (AE) necessitating withdrawal from study were d
ngina.
B  bisoprolol; C  carvedilol; CHF  chronic heart failure; M  metoprolol.uring the first week on their new beta-blocker. Improved rolerability has been reported when the initial dose of the
econd beta-blocker is reduced (15); this may be a prudent way
o exchange beta-blockers in the clinical setting.
tudy limitations. The reduction in resting heart rate of 4
eats/min between carvedilol and bisoprolol raises the issue
f beta-blocker dose equipotency. Receptor kinetics and
iffering beta-blocker pharmacokinetic and pharmacody-
amic properties may give rise to differences in the extent
nd duration of beta- and alpha-blockade. It is, however,
eassuring that no difference in brachial blood pressure was
etected, as was observed in the COMET (11). Limited
linical data are available to guide dose matching (15,19,21),
hich is further complicated by extrapolation of clinical trial
ata on short-acting metoprolol tartrate to metoprolol
uccinate (21). Our dose-matching protocol was based on
oses used in landmark clinical trials, all of which showed
imilar reductions in mortality (1–3). From a practical
erspective, these are the doses used in up-titration proto-
ols, irrespective of perceived relative equipotency.
Other limitations include the relatively small cohort and
hort treatment periods. It should be noted, however, that
he study was sufficiently powered to demonstrate changes
n outcomes. Additionally, given the pharmacokinetics of
he beta-blockers examined, a carryover effect from each
rug is unlikely despite potential alterations in receptor
ensity and sensitivity caused by their usual beta-blocker, a
otion supported by the observed reduction of NT-proBNP
nd FEV1 back to baseline levels at 4 weeks after recommence-
ent of the original carvedilol in a large subgroup. The
ajority of patients recruited to the study were on carvedilol at
he onset. This introduces selection bias toward subjects with
OPD who are able to tolerate nonselective beta-blockade.
atients with a previous severe intolerance to any of the
eta-blockers were also excluded for safety reasons. Although
he study was open label, the key outcome measures of
espiratory function and NT-proBNP were acquired and
to M B to C M to C B to M M to B
— — — 1 (2) —
— 3 (6) — — —
— 1 (2) — — —
— — — — —
3 (6) — 1 (2) 2 (4) 1 (2)
— — 1 (2) — —
— — 1 (2) — —
— — — — —
— — — 2 (4) —
— 1 (2) — 1 (2) —
— — — 1 (2) —
— 2 (4) — 1 (2) —
3 (6) — — — 1 (2)
yspnea, clinically adjudicated to be caused by worsening heart failure; 1 patient had concomitantC
ue to deported by scientists blinded to the study.
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April 27, 2010:1780–7 Beta-Blockade in Heart Failure and COPDonclusions
he present study demonstrates that in a cohort of patients
ith CHF with or without coexistent COPD who are able
o tolerate beta-blockers, switching between B1Bs and
arvedilol results in demonstrable changes in airway func-
ion. Switching from B1Bs to carvedilol causes short-term
eduction of central augmented pressure and NT-proBNP,
powerful prognostic marker in chronic heart failure.
cknowledgments
he authors wish to thank Drs. Sharon Chih, Ping Nee
ee, Dipak Kotecha, Michele McGrady, Susan Wright,
hick Foo, Queenie Lo, Graham Jones, Deborah Yates,
ary Gazibarich, and Alan Glanville for their academic
nput into the study. They also acknowledge Mss. Claire
oates, Sharon Stuart, Robyn Funston, Marina Skiba, and
r. Marcus Juul for their assistance in data acquisition and
nput.
eprint requests and correspondence: Assoc. Prof. Christopher
ayward, Cardiology Department, St. Vincent’s Hospital, Liver-
ool Street, Sydney, New South Wales 2010, Australia. E-mail:
shayward@stvincents.com.au.
EFERENCES
1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55.
2. The MERIT-HF Study Group. Effect of metoprolol CR/XL in
chronic heart failure: Metoprolol CR/XL Randomized Intervention
Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:
2001–7.
3. The CIBIS-II Investigators and Committees. The Cardiac Insuffi-
ciency Bisoprolol study II (CIBIS-II). Lancet 1999;353:9–13.
4. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic
challenges in patients with coexistent chronic obstructive pulmonary
disease and chronic heart failure. J Am Coll Cardiol 2007;49:171–80.
5. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for
chronic obstructive pulmonary disease. Cochrane Database Syst Rev
2005;4:CD003566.
6. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R,
McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with
New York Heart Association class IV heart failure. J Am Coll Cardiol
1999;33:924–31. b7. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary dis-
ease: GOLD executive summary. Am J Respir Crit Care Med
2007;176:532–55.
8. Urbaniak GC, Plous S. Research Randomizer. Available at: http://
www.randomizer.org/form.htm. Accessed between July 7, 2005, and
June 19, 2008.
9. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A
randomised controlled comparison of tiotropium and ipratropium in
the treatment of chronic obstructive pulmonary disease. The Dutch
Tiotropium Study Group. Thorax 2000;55:289–94.
0. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of
once-daily inhaled tiotropium in chronic obstructive pulmonary dis-
ease. Eur Respir J 2002;19:217–24.
1. Olsson LG, Swedberg K, Cleland JG, et al. Prognostic importance of
plasma NT-pro BNP in chronic heart failure in patients treated with
a beta-blocker: results from the Carvedilol Or Metoprolol European
Trial (COMET). Eur J Heart Fail 2007;9:795–801.
2. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira
A. N-terminal-pro-brain natriuretic peptide predicts outcome after
hospital discharge in heart failure patients. Circulation 2004;110:
2168 –74.
3. Zugck C, Kruger C, Durr S, et al. Is the 6-minute walk test a reliable
substitute for peak oxygen uptake in patients with dilated cardiomy-
opathy? Eur Heart J 2000;21:540–9.
4. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L.
Differential effects of beta-blockers in patients with heart failure: a
prospective, randomized, double-blind comparison of the long-term
effects of metoprolol versus carvedilol. Circulation 2000;102:546–51.
5. Maack C, Elter T, Nickenig G, et al. Prospective crossover compar-
ison of carvedilol and metoprolol in patients with chronic heart failure.
J Am Coll Cardiol 2001;38:939–46.
6. Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to
carvedilol in patients with chronic heart failure. Heart 2000;84:615–9.
7. Galatius S, Gustafsson F, Atar D, Hildebrandt PR. Tolerability of
beta-blocker initiation and titration with bisoprolol and carvedilol in
congestive heart failure—a randomized comparison. Cardiology 2004;
102:160–5.
8. Camsari A, Arikan S, Avan C, et al. Metoprolol, a beta-1 selective
blocker, can be used safely in coronary artery disease patients with
chronic obstructive pulmonary disease. Heart Vessels 2003;18:188–92.
9. Di Lenarda A, Remme WJ, Charlesworth A, et al. Exchange of
beta-blockers in heart failure patients. Experiences from the poststudy
phase of COMET (the Carvedilol Or Metoprolol European Trial).
Eur J Heart Fail 2005;7:640–9.
0. Tygesen H, Andersson B, Di Lenarda A, et al. Potential risk of
beta-blockade withdrawal in congestive heart failure due to abrupt
autonomic changes. Int J Cardiol 1999;68:171–7.
1. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with chronic
heart failure in the Carvedilol Or Metoprolol European Trial (COMET):
randomised controlled trial. Lancet 2003;362:7–13.
ey Words: heart failure y chronic obstructive pulmonary disease y
eta-blocker.
